Healthcare Industry Allergy Diagnostics and Therapeutics Market | Page 2

Your Catalyst To a Lucrative Business
Various types of allergens are drug allergens, inhaled allergens, food allergens, and others. Inhaled allergens
held the highest industry share over the past couple of years because of numerous cases of air pollution
based allergies.
Based on end uses, the industry is trifurcated into diagnostics laboratories, and academic research in stitutes.
Types of tests mainly include the following: in-vitro, patch, intradermal, skin prick, and in vivo. As per drug
classes, the divisions are immunotherapy, autoinjectable epinephrine, immunomodulators, decongestants,
nasal anticholinergics, leukotriene inhibitors, mast cell stabilizers, corticosteroids, and antihistamines.
Geographically, the worldwide allergy diagnostics and therapeutics market is divided into Asia Pacific,
Europe, North America, Latin America, and the Middle East & Africa. Over t he past couple of years, North
America has been dominating the global market in terms of revenue earnings. The region may continue
leading the industry over the forecast period. Growing acceptance of in vitro blood tests, awareness about
allergy diagnostics, and rising cases of allergic respiratory anomalies are drivers of this region.
Europe is expected to register a high rate of growth because the region boasts of a mature pharmaceuticals
industry. Surging demand for therapeutics is also a prominent regional driver. Other factors are rising cases
allergic conditions and a rapidly expanding geriatric population. Asia Pacific may expand rapidly till 2022
owing to a rapidly developing medical infrastructure and surging demand for minimally invasive diagn ostics
solutions.
The global allergy diagnostics and therapeutics market is a highly fragmented one with a host of companies
continuously striving towards larger market shares. Lincoln Diagnostics, Siemens Healthcare, Hitachi Chemical
Diagnostics, Alcon Laboratories, and Hycor Biomedical are some of the prominent competitors operating in
the global market.
In May 2016, Thermo Fisher Scientific licensed ProBioGen AG’s GlymaxX® technology for the development of
allergy diagnostics. ProBioGen AG is a Germany based CDMO (contract development and manufacturing
organization) & technology provider. Its key areas of focus are GMP production of biopharmaceuticals,
process development, and cell lining engineering. The GlymaxX® technology yields antibodies with lower
fucose content, is applicable to different types of species, needs no culture additives, and can even lead to
enhanced productivity.
Browse Related Category Market Reports @
https://www.hexaresearch.com/research-category/clinical-diagnostics-industry
Follow Us: